ischemia

Case Q&A

Pathogenesis of Pressure Injuries

03/07/2024

Stephen M. Milner, MBBS, BDS, DSc (Hon) FRCSE, FACS¹; Ryan Mathis, MD²

Stephen M. Milner, MBBS, BDS, DSc (Ho...

This Case Q&A discusses pressure injuries, with context for spinal cord injuries.

This Case Q&A discusses pressure...

03/07/2024

ePlasty

Original Contribution

Activated Clotting Time and Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS-CTO Registry

12/05/2023

Bahadir Simsek, MD¹; Athanasios Rempakos, MD¹; Spyridon Kostantinis, MD¹; Michaella Alexandrou, MD¹; Sevket Gorgulu, MD²; Khaldoon Alaswad, MD³; Jarrod D. Frizzell, MD⁴; Ufuk Yildirim, MD⁵; Paul Poommipanit, MD⁶; Nazif Aygul, MD⁷; Nidal Abi Rafeh, MD⁸, Rodrigo Bagur, MD, PhD⁹; Rhian Davies, MD¹⁰; Omer Goktekin, MD¹¹; James W. Choi, MD¹²; Niranjan Reddy, MD¹³; Philip Dattilo, MD¹⁴; Jimmy Kerrigan, MD¹⁵; Elias V. Haddad, MD¹⁵; Olga C. Mastrodemos, BA¹; Bavana V. Rangan, BDS, MPH¹; Judit Karacsonyi, MD, PhD¹; Salman S. Allana, MD¹; Kathleen E. Kearney, MD¹⁶; Yader Sandoval, MD¹; M. Nicholas Burke, MD¹; Emmanouil S. Brilakis, MD, PhD¹; Lorenzo Azzalini, MD, PhD, MSc¹⁶

Bahadir Simsek, MD1; Athanasios Rempa...

The authors evaluated the association between activated clotting time and in-hospital clinical outcomes in a large international multicenter chronic total occlusion-percutaneous coronary intervention registry.

The authors evaluated the...

12/05/2023

Journal of Invasive Cardiology

Paclitaxel DCB 12-Month PREVAIL Study Results Figure 1

Original Contribution

Paclitaxel Drug-Coated Balloon for the Treatment of De Novo Small-Vessel and Restenotic Coronary Artery Lesions: 12-Month Results of the Prospective, Multicenter, Single-Arm PREVAIL Study

11/01/2021

Azeem Latib, MD^1,2; Pierfrancesco Agostoni, MD, PhD³; Jo Dens, MD, PhD⁴; Mark Patterson, MBBS, PhD⁵; Patrizio Lancellotti, MD, PhD⁶; Frankie C.C. Tam, MD⁷; Carl Schotborgh, MD⁸; Elvin Kedhi, MD⁹; Pieter Stella, MD, PhD¹⁰;
Cheryl Shen, MS¹¹; Gwenn Wetzels, PhD¹¹; Luca Testa, MD¹²; for the PREVAIL Study Investigators

Azeem Latib, MD1,2; Pierfrancesco Ag...

The PREVAIL study evaluated the safety and effectiveness of a paclitaxel DCB for the treatment of coronary de novo and ISR lesions in patients with symptomatic ischemic heart disease.

The PREVAIL study evaluated the...

11/01/2021

Journal of Invasive Cardiology

Case Series

Clinical Pearls for Management of Postoperative Deep Vein Arterialization Patients Following Lower Extremity Minor Amputation: A Case Series

07/08/2020

Michael Brown, DPM; Guy Pupp DPM, FACFAS

Ascension Providence, Providence Park Hospital, Southfield, Michigan

Michael Brown, DPM; Guy Pupp DPM, FAC...

CLI is the end stage of PAD and occurs in 1% to 3% of PAD patients. Patients commonly present with life-changing symptoms such as severe rest pain, ulcers, or gangrenous changes and reduced quality of life.

CLI is the end stage of PAD and...

07/08/2020

Vascular Disease Management

Commentary

The Benefit of Iloprost in the Prevention of Adverse Effects Related to Ischemia

11/06/2008

Nicholas J. Morrissey, MD

The report by de Donato and colleagues on the impact of iloprost on outcomes after the treatment of acute ischemia provides insight into the mechanism and prevention of adverse effects related to ischemia and its treatment. The authors based...

The report by de Donato and...

11/06/2008

Vascular Disease Management